28 July 2026 June 2026 Quarterly Activity Report and Cash Flow Statement Argent Biopharma Ltd (ASX: RGT) is pleased to update the market for the June 2026 quarter, including material developments up to the date of this report, and attaches its Appendix 4C Quarterly Cash Flow report for...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Argent Biopharma
- RGT Executes Global CannEpil Licensing Deal for US$5.5M
- Half Yearly Report and Accounts
- Provisional Patent Lodged with USPTO for NanoBodies Platform
- CannEpil - Largest Commercial Shipment Arrives in Ireland
- Streamlined Acquisition of AusCann Assets
Later from Argent Biopharma
- CannEpil Global Licence Expands into Veterinary Healthcare
- Notification of cessation of securities - RGT
- US Veterinary Development Programme for CannEpil Commences
- $250,000 in Funding Received under Financing Facility
- Proposed issue of securities - RGT
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma